Palvella Therapeutics, Inc Total Liabilities
Palvella Therapeutics, Inc total liabilities. Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has total liabilities worth $36.58 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Palvella Therapeutics, Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Palvella Therapeutics, Inc (2020–2025)
Total liabilities of Palvella Therapeutics, Inc from 2020 to 2025. This chart illustrates how Palvella Therapeutics, Inc's total liabilities have evolved over time, based on quarterly financial data.
Palvella Therapeutics, Inc Competitors by Total Liabilities
The table below lists competitors of Palvella Therapeutics, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Garware Hi-Tech Films Limited
NSE:GRWRHITECH
|
India | Rs3.55 Billion |
|
Chongqing Fuling Electric Power Industrial Co Ltd
SHG:600452
|
China | CN¥731.84 Million |
|
Lily Group Co Ltd
SHG:603823
|
China | CN¥820.71 Million |
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
China | CN¥11.78 Billion |
|
Wuxi Rural Commercial Bank Co Ltd
SHG:600908
|
China | CN¥267.88 Billion |
|
Dicker Data Ltd
AU:DDR
|
Australia | AU$1.09 Billion |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
China | CN¥551.75 Million |
|
GQG PARTNERS CDI/1/1
F:6P1
|
Germany | €50.29 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Palvella Therapeutics, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Palvella Therapeutics, Inc total assets.
Liquidity & Leverage Metrics
Palvella Therapeutics, Inc Total Liabilities Ratios Explained
Palvella Therapeutics, Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Palvella Therapeutics, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual total liabilities of Palvella Therapeutics, Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.58 Million | +23.21% |
| 2024-12-31 | $25.63 Million | +124.25% |
| 2023-12-31 | $11.43 Million | -71.21% |
| 2022-12-31 | $39.70 Million | -61.39% |
| 2021-12-31 | $102.81 Million | +38.96% |
| 2020-12-31 | $73.98 Million | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more